Annual medication readjustment: increase will be up to 4.33%

Effective as of April 1, the annual medication readjustment was defined by the Medicines Market Regulation Chamber (CMED).

According to the entity, the adjustment, made annually, allows more transparency in what is charged by pharmacies and stimulates the competitiveness of the drug industry. This year, the rate will increase by up to 4.33%.

The percentage already had an average estimate to be followed. In February, the Association of the Pharmaceutical Research Industry (Interfarma), said that the increase could be even greater, around 4.46%.

But only on Monday (01), CMED defined the percentage of 4.33%, within the number stipulated by Interfarma.

It is worth remembering that the increase is not done automatically in prices. That is, it does not mean that the remedies will necessarily go up.

According to the Ministry of Health, the readjustment is only a permitted ceiling. Each pharmaceutical company can choose a percentage within this range, according to its commercial strategy .

Read more: Consumer rights to the price of medicines

How is the readjustment done?

The readjustment is a calculation used to correct drug prices on an equal basis annually.

It is usually done taking into account some factors that may have an impact on the value, such as inflation in the last 12 months, the production of medicines in industries, the exchange rate and the electricity tariff.

And they are valid for those drugs that need a prescription to be sold.

In addition, some groups of drugs have different adjustment ceilings – but all within this range of, at most, 4.33%.

This is because the different outlets in the market are taken into account, be it high, moderate or low competition. That is, the more companies or brands manufacturing, the greater the competition.

Medicines like omeprazole and pantoprazole are part of the high competition group, as there are several brands, including generics, available. These can have the maximum readjustment of up to 4.33%.

Since ketoconazole and tramadol , which are antifungal and participate in the competition moderate group have a slightly smaller increase compared to the first.

Those with low competition, or concentrated competition, such as betamethasone and dexamethasone , have the lowest adjustment in the category.

According to the Ministry of Health, companies that do not comply with prices within the adjustment, or increase the percentage more than the established, can pay a fine of up to 9.7 million.